In July, I wrote a blog entitled, "Controversy: Alive and Well at Bio International." The second subhead reads, "Clinical Trial Diversity Still Sits at the Back of the Bus." Apparently this got some folks' attention. James Gillespie, Ph.D., J.D. is the president of the Center for Healthcare Innovation. He decided to give me a call about my blog. I half expected the call to be a criticism for my choice of words, but to my delight, it was just the opposite.
Eight Steps To More Productive Observational Studies
The automobile industry is in a precarious state. With factories designed to churn out light trucks, SUVs, and other gas-guzzlers, the industry has been ill-prepared for the shift toward energy-efficient vehicles. Is this an allegory for the pharmaceutical industry? Perhaps.
Oncology Clinical Trials And Studies
Oncology is currently ICON's fastest-growing therapeutic area and a testament to our success in conducting oncology clinical trials. To date, ICON has conducted over 870 oncology studies, assessing over 143,000 patients at nearly 24,000 sites worldwide.